Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line.

H Nakamura, … , N G McElvaney, R G Crystal


Research Article

The respiratory manifestations of cystic fibrosis (CF) are characterized by neutrophil-dominated airway inflammation. Since a variety of inflammatory stimuli are capable of inducing bronchial epithelial cells to express the gene for IL-8, a cytokine that attracts and activates neutrophils, mediators in respiratory epithelial lining fluid (ELF) of CF individuals might induce IL-8 production by epithelial cells, thus recruiting neutrophils to the airways. BET-1A human bronchial epithelial cells at rest or incubated with normal ELF showed little IL-8 gene expression, but after incubation with CF ELF, a marked increase in IL-8 transcript levels was observed. CF ELF contained high levels of neutrophil elastase (NE) and various serine protease inhibitors prevented CF ELF from inducing IL-8 gene expression in BET-1A cells, suggesting that NE was the dominant inducer for IL-8 production in CF ELF. The addition of purified NE caused BET-1A cells to increase IL-8 gene transcription with accumulation of mRNA transcripts and to release IL-8-like neutrophil chemotactic activity. These observations suggest a self-perpetuating inflammatory process on the CF bronchial surface where NE released by neutrophils induced the bronchial epithelium to secrete IL-8, which in turn recruits additional neutrophils to the bronchial surface.

Find the latest version:

http://jci.me/115738-pdf
Neutrophil Elastase in Respiratory Epithelial Lining Fluid of Individuals with Cystic Fibrosis Induces Interleukin-8 Gene Expression in a Human Bronchial Epithelial Cell Line

Hidenori Nakamura, Kunihiko Yoshimura, Noel G. McElvaney, and Ronald G. Crystal
Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892

Abstract

The respiratory manifestations of cystic fibrosis (CF) are characterized by neutrophil-dominated airway inflammation. Since a variety of inflammatory stimuli are capable of inducing bronchial epithelial cells to express the gene for IL-8, a cytokine that attracts and activates neutrophils, mediators in respiratory epithelial lining fluid (ELF) of CF individuals might induce IL-8 production by epithelial cells, thus recruiting neutrophils to the airways. BET-1A human bronchial epithelial cell lines were infected with normal ELF, and showed little IL-8 gene expression, but after incubation with CF ELF, a marked increase in IL-8 transcript levels was observed. CF ELF contained high levels of neutrophil elastase (NE) and various serine proteinase inhibitors prevented CF ELF from inducing IL-8 gene expression in BET-1A cells, suggesting that NE was the dominant inducer for IL-8 production in CF ELF. The addition of purified NE caused BET-1A cells to increase IL-8 gene transcription with accumulation of mRNA transcripts and to release IL-8-like neutrophil chemotactic activity. These observations suggest a self-perpetuating inflammatory process on the CF bronchial surface where NE released by neutrophils induced the bronchial epithelium to secrete IL-8, which in turn recruits additional neutrophils to the bronchial surface. (J. Clin. Invest. 1992. 89:1478-1484.) Key words: cytokine • anti-serine pro tease • bronchial epithelium • neutrophil chemoattractant • air way inflammation

Introduction

Cystic fibrosis (CF) is a lethal hereditary disorder caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, a 250 kb, 27 exon gene on chromosome 7 (1-4). The CFTR gene product, a 168-kD glycosylated membrane protein, is thought to function as a chloride channel regulated by cytoplasmic protein kinases (3, 5-9). Although the link between mutations in the CFTR gene and the pathogenesis of CF are not completely understood, the lethal clinical manifestations of CF are clearly related to the thick, infected mucus and chronic neutrophil-dominated inflammation on the epithelial surface of the airways (1, 10-14). The large numbers of neutrophils place the airway epithelium in great jeopardy consequent to the exposure to potent neutrophil mediators, including neutrophil elastase, reactive oxygen species, and probably a variety of cytokines (10-14). Over time, this potent armamentarium overwhelms the local defense of the epithelium, resulting in damage and derangement of the airways (1, 13, 15-19).

In this context, it is apparent that recruitment of neutrophils to the bronchial surface is a two-edged sword, necessary to contend with the local infection, but dangerous to the vulnerable epithelium. While it is not clear whether the numbers of neutrophils that are recruited are appropriate for the level of infection, in excess, or insufficient for host defense, it is relevant to ask the question: what signals the neutrophils to accumulate on the respiratory epithelial surface in CF? The answer is likely complex, and undoubtedly involves a variety of mechanisms, including chemoattractants released by alveolar macrophages as well as those linked to the complement system (13, 14, 20-24). The present study was designed to expand these concepts to include bronchial epithelial cells as a source of chemoattractants for neutrophils. Based on the knowledge that human bronchial epithelial cells can release the potent neutrophil chemoattractant IL-8 in response to a variety of stimuli (25-28), we hypothesized that the epithelial lining fluid (ELF) of individuals with CF contains signals capable of inducing the expression of the IL-8 gene in bronchial epithelial cells. The data demonstrate that CF ELF does contain such signals, and interestingly, the dominant signal is neutrophil elastase (NE), suggesting a cycle of inflammation on the respiratory epithelium in CF, to where neutrophils are attracted and NE is released, resulting in induction of expression of IL-8 by the respiratory epithelium, and the recruitment of more neutrophils.

Methods

Study population. The study population included eight individuals with cystic fibrosis (four male, four female; average age of 28±2 yr [all data are expressed as mean±standard error of the mean; all statistical comparisons were done with the two-tailed Student's t test]). All had a positive sweat chloride test, chronic sputum production, respiratory tract colonization with Pseudomonas aeruginosa, and moderate impairment of lung volumes and flow rates (as percentage predicted FEV1, 41±4; FVC 52±5) (1, 29). The average Shwachman score was 56±6 (30). All were lifelong nonsmokers. As a control, seven normal nonsmoking individuals were evaluated (four male, three female; average age of 29±3 yr). None had a history of pulmonary symptoms and all had normal physical examination, chest roentgenograms, and lung function tests.

Recovery of respiratory epithelial lining fluid. Bronchoalveolar lavage was used to obtain the respiratory ELF as previously described (31). Cells were isolated from the fluid by centrifugation, and total and

---

1. Abbreviations used in this paper: AAPV-CMK, methoxy-succinylalanlyl-alanyl-prolyl-valyl-chloromethyl-ketone; CF, cystic fibrosis; CFTR, CF transmembrane conductance regulator; ELF, epithelial lining fluid; NE, neutrophil elastase; SLPI, secretory leukoprotease inhibitor.

Address reprint requests to Ronald G. Crystal, M.D., Pulmonary Branch, Building 10, Room 6D03, National Institutes of Health, Bethesda, MD 20892.

Received for publication 11 June 1991 and in revised form 13 December 1991.

The Journal of Clinical Investigation, Inc.
Volume 89, May 1992, 1478-1484
differential cell counts determined. ELF volumes were quantified by the urea method (32). The fluid was maintained at ~70° until evaluated.

**Neutrophil elastase, neutrophil elastase inhibitors, and IL-8.** NE activity in ELF was quantified using the NE-specific substrate methoxy-succinyl-alamyl-alamyl-prolyl-valyl-nitroanilide (Sigma Chemical Co., St. Louis, MO) as previously described (33). Purified NE (Elastin Products Co., Inc., Pacific, MO) was titrated against a purified human α1-antitrypsin (α1AT) active standard (33). Serine protease inhibitors used as inhibitors of NE in this study included human recombinant secretory leukoprotease inhibitor (SLPI; Synergen, Boulder, CO), human plasma α1AT (Calbiochem Corp., La Jolla, CA), PMSF (Calbiochem), and the NE-specific inhibitor methoxy-succinyl-alamyl-alamyl-prolyl-valyl-chloromethyl ketone (AAPV-CMK; Sigma). All inhibitors were tested in vitro for their activity in inhibiting NE as previously described (33). IL-8 levels in ELF were measured using an enzyme-linked IL-8 immunoassay (Quantikine; R&D Systems, Minneapolis, MN). The effect of NE on the form of IL-8 was evaluated with Western analysis of IL-8 incubated with varying concentrations of NE (ranging from 10 nM to 10 μM) similar to that found in CF ELF, using 15% SDS polyacrylamide gel electrophoresis and a polyclonal anti-human IL-8 antibody (Biosource International, Westlake Village, CA).

**Cell cultures.** BET-1A cells, an SV40 transformed human bronchial epithelial cell line (gift of J. E. Lechner, Laboratory of Human Carcinogenesis, LHC, National Cancer Institute) were cultured at 37° in serum-free LHC-9 medium with 25 μg/ml fungizone, 25 U/ml penicillin, and 25 μg/ml streptomycin (all from Biofluids Inc., Rockville, MD) (34). The surface of the culture dishes were coated with a mixture of human fibropectin (10 μg/ml; Collaborative Research Inc., Bedford, MA), collagen (Vitrogen 100, 30 μg/ml; Collagen Corp., Palo Alto, CA), and crystallized BSA (10 μg/ml; Biofluids) dissolved in LHC basal media (Biofluids) (35). All studies were carried out when the cells were 80–90% confluent.

**IL-8 mRNA transcript levels.** The levels of IL-8 mRNA transcripts and control β-actin mRNA transcripts were evaluated by Northern analysis and by slot blot hybridization (36, 37). Total cellular RNA was isolated by the guanidinium thiocyanate-CsCl gradient method (38). For Northern analyses, RNA (10 μg/lane) was subjected to agarose gel electrophoresis and transferred to a nylon membrane (Nytran; Schleicher and Schuell Inc., Keene, NH). The filter was hybridized with probes labeled with 32P by the random priming method (39, 40). The IL-8 probe was a 750-bp cDNA derived from clone pPB248 containing the sequence from the PstI site of exon 1 to the BamHI site of exon IV (25). It was constructed after reverse transcription of RNA from lipopolysaccharide (Escherichia coli 0127:88; Difco Laboratories, Detroit, MI) stimulated human blood monocytes followed by amplification of IL-8 cDNA using the polymerase chain reaction with IL-8 exon-specific oligonucleotide primers (NAFS1, 5'-ATTTCTGTGAGCCTCTTGGTGAAAGGTGC-3' and NAFS2, 5'-TTGTTGATCCTGCGTACAGAC-3') (25, 41–43). As a control β-actin probe, the cDNA clone pHF3A-1 was used (44). For normal and CF ELF studies and NE dose-dependence and time-course studies, mRNA transcript levels were quantified by slot blot hybridization analysis and densitometry (Ultron Laser Densitometer, Pharmacia LKB, Piscataway, NJ) using 10 μg RNA as the starting material and the IL-8 and β-actin probes described above.

**Modulation of IL-8 mRNA transcript levels.** Based on prior observations that tumor necrosis factor-α (TNF) induced BET-1A cells to express the IL-8 gene (25), human recombinant TNF (200 U/ml, 20 U/ng; Genzyme Corp., Boston, MA) was used as a positive control and prototype inflammatory stimulus. In parallel cultures, respiratory ELF (1 μl ELF/ml culture media) from normals and individuals with CF were added to the cell culture, incubated for 3 h at 37°, and IL-8 and β-actin mRNA levels evaluated by Northern or slot blot analysis.

To determine the nature of the signals in CF ELF that induced BET-1A cells to express the IL-8 gene, the CF ELF was incubated for 10 min, 37° alone, or in the presence of the various protease inhibitors, including rSLPI (500 nM), α1AT (500 nM), PMSF (1 μM), or AAPV-CMK (1 μM). In parallel cultures, the mouse monoclonal anti-human TNF antibody (Genentech, Inc., South San Francisco, CA) was added. Based on the observation that the serine protease inhibitors prevented CF ELF from inducing IL-8 gene expression in the BET-1A cells, the studies were also carried out using purified NE alone or incubated with protease inhibitors in a similar fashion before their addition to the cell culture. The dose-dependent studies with NE were carried out using 0–50 nM of purified NE for 3 h. The time-course studies used 10 nM of NE and subsequent incubation of the BET-1A cells for 0–24 h. The dose and time-course studies were complicated by the effect of NE on detaching cells from the culture plate observed at concentrations of NE > 50 nM or incubation with 10 nM for > 24 h, and these effects were limited to these conditions and times. Cell viability assessed by trypan blue dye exclusion was > 95% in all studies.

**IL-8 release by neutrophil elastase-stimulated BET-1A cells.** To demonstrate that NE induces bronchial epithelial cell to release functional IL-8, neutrophil chemotactic activity in the culture supernatants was evaluated from resting and NE-stimulated BET-1A cells as well as in ELF from individuals with CF and normal individuals using a modified Boyden chamber (45). Neutrophils were isolated (> 95% pure) from blood of normal individuals by centrifugation through Monopoly-Resolving medium (Flow Laboratories, Irvine, CA) (46) and resuspended in Hank's balanced salt solution (Mediatech, Herndon, VA) at 2 × 106 cells/ml. Chemotactic activity was expressed as the percentage of an FMLP (10−7 M; Sigma) positive control. Controls included culture media alone, human recombinant monocyte IL-8 (5 ng/ml, Upstate Biotechnology, Inc., Lake Placid, NY), culture media from resting cells, and NE alone. Conditioned media from NE-stimulated (10 nM) BET-1A cells (all incubations 24 h, 37°) and ELF from normals or individuals with CF were evaluated in the absence or presence of a rabbit IgG anti-IL-8 antibody or nonimmune IgG (100 μg/ml, Endogen, Boston, MA) and in the presence of the NE-specific inhibitor AAPV-CMK (1 μM).

**Level of modulation of IL-8 gene expression in BET-1A cells by neutrophil elastase.** Modulation of the relative rate of IL-8 gene transcription by NE was evaluated using nuclear run-on analysis (47). Nuclear extracts were isolated from 5 × 107 BET-1A cells at rest, stimulated with NE (10 nM), or with NE in the presence of α1AT (500 nM) or SLPI (500 nM). The nuclei were incubated with 5 mM ATP, 2 mM CTP, 2 mM UTP, 330 μCi [α-32P]GTP (Amersham Corp., Arlington Heights, IL), and RNase inhibitor (RNasin, 2 U/μl; Promega Biotec, Madison, WI) to label actively transcribed RNA. RNA was labeled with the acid guanidinium thiocyanate-phenol-chloroform method (RNAzol B; Cinna/Biotex Laboratories International Inc., Friendwood, TX) (48). 32P-labeled nascent RNA was purified by Sephadex G-50 column chromatography (5 prime → 3 prime, Inc., West Chester, PA) and hybridized to excess amounts (5 μg) of DNA targets immobilized on Nytran (Schleicher and Schuell Inc.). The DNA targets included plasmids containing an IL-8 cDNA (pPB248), a partial genomic clone for c-myec (Lofstrand Labs, Gaithersburg, MD), a human β-actin cDNA (pHFB3A-1), or as a negative control, the plasmid pBluescript II SK+ (pBS, Stratagene, Inc., La Jolla, CA). After 36 h, the membranes were washed, exposed to RNA A: 5 (5 μg/ml) and RNA T: (5 μ/ml, followed by proteins K (50 μg/ml; Boehringer Mannheim Biochemicals, Indianapolis, IN), and evaluated by autoradiography.

To evaluate the stability of IL-8 mRNA transcripts after NE stimulation, BET-1A cells were treated with actinomycin D (10 μg/ml; United States Biochemicals, Cleveland, OH) for 30 min, 1, 2, and 4 h, and the following conditions were evaluated: BET-1A cells at rest, after exposure to NE (10 nM, 3 h), or after the addition of the protein synthesis inhibitor, cycloheximide (10 μg/ml, 3 h; Sigma). Total cellular RNA was extracted, IL-8 mRNA levels were evaluated by Northern analysis as described above, and quantified using laser densitometry.

**Results**

**Epithelial lining fluid in cystic fibrosis.** The relative amounts of ELF recovered from individuals with CF was similar to that of
Table I. Evaluation of Respiratory Epithelial Lining Fluid Recovered by Bronchoalveolar Lavage From Normals and Individuals with Cystic Fibrosis

<table>
<thead>
<tr>
<th>Study group</th>
<th>Patient no./sex/age</th>
<th>Recovered ELF</th>
<th>Total cells</th>
<th>Macrophages</th>
<th>Neutrophils</th>
<th>Lymphocytes</th>
<th>NE in ELF (µM)</th>
<th>IL-8 in ELF (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>7</td>
<td>1.12±0.17*</td>
<td>14.7±2.4</td>
<td>12.5±2.0</td>
<td>0.4±0.3</td>
<td>1.7±0.4</td>
<td>ND‡</td>
<td>ND</td>
</tr>
<tr>
<td>CF</td>
<td>8</td>
<td>0.97±0.24</td>
<td>121±29</td>
<td>20±4</td>
<td>101±26</td>
<td>0</td>
<td>31±10</td>
<td>35±13</td>
</tr>
<tr>
<td>1/F/26</td>
<td></td>
<td>0.18</td>
<td>256</td>
<td>46</td>
<td>210</td>
<td>0</td>
<td>86</td>
<td>108</td>
</tr>
<tr>
<td>2/M/29</td>
<td></td>
<td>1.27</td>
<td>149</td>
<td>24</td>
<td>125</td>
<td>0</td>
<td>66</td>
<td>68</td>
</tr>
<tr>
<td>3/M/31</td>
<td></td>
<td>0.74</td>
<td>245</td>
<td>25</td>
<td>221</td>
<td>0</td>
<td>30</td>
<td>38</td>
</tr>
<tr>
<td>4/M/26</td>
<td></td>
<td>0.75</td>
<td>55</td>
<td>33</td>
<td>51</td>
<td>0</td>
<td>7</td>
<td>11</td>
</tr>
<tr>
<td>5/F/26</td>
<td></td>
<td>0.27</td>
<td>37</td>
<td>8</td>
<td>29</td>
<td>0</td>
<td>9</td>
<td>16</td>
</tr>
<tr>
<td>6/F/29</td>
<td></td>
<td>2.52</td>
<td>107</td>
<td>15</td>
<td>92</td>
<td>0</td>
<td>18</td>
<td>17</td>
</tr>
<tr>
<td>7/F/29</td>
<td></td>
<td>0.91</td>
<td>73</td>
<td>22</td>
<td>51</td>
<td>0</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>8/M/22</td>
<td></td>
<td>1.08</td>
<td>47</td>
<td>16</td>
<td>32</td>
<td>0</td>
<td>26</td>
<td>14</td>
</tr>
</tbody>
</table>

Patient no., patients with CF numbered consecutively. * Mean±standard error or the mean. ‡ ND, not detected.

normals (Table I, P = 0.63). The total numbers of inflammatory cells in ELF were markedly increased in CF, averaging more than eightfold greater than that of normals (P < 0.03). The increase in the number of inflammatory cells in CF ELF was dominated by neutrophils, with > 250-fold increase over the neutrophil numbers in normal ELF (P < 0.005). High levels of active neutrophil elastase were readily detectable in all CF ELF samples with an average of 31±10 µM (range 7–86 µM) whereas normal ELF did not contain any active NE. Interestingly, IL-8 was present in all CF ELF with an average of 35±13 nM (range 8–108 nM) but was undetectable in normal ELF. Western blot analysis of the IL-8 incubated with varying amounts of NE showed no evidence of degradation of the IL-8 (not shown).

Cystic fibrosis epithelial lining fluid induced IL-8 gene expression in bronchial epithelial cells. Northern analyses demonstrated that resting BET-1A cells contained very little, if any, IL-8 mRNA transcripts (Fig. 1, lane 1). As a positive control, recombinant TNF induced expression of the expected 1.8-kb IL-8 mRNA transcripts (lane 2). Importantly, although ELF from normal individuals had no influence on IL-8 gene expression in the BET-1A cells, CF ELF induced the expression of IL-8 mRNA transcripts (lanes 3 and 4). In contrast to the difference in IL-8 mRNA transcripts when ELF from normals and individuals with CF were incubated with BET-1A cells, control β-actin mRNA transcript levels did not change (lanes 1–4).

Quantification of IL-8 mRNA levels in BET-1A cells incubated with normal or CF ELF demonstrated that ELF from the seven normal individuals did not induce IL-8 gene expression, but ELF from all eight CF individuals was capable of inducing IL-8 mRNA transcripts in BET-1A cells (Fig. 2A). In contrast to the differences in IL-8 transcripts induced by normal and CF ELF, neither ELF changed β-actin mRNA transcript levels (B).

Neutrophil elastase inhibitors prevent cystic fibrosis epithelial lining fluid induction of IL-8 gene expression in bronchial epithelial cells. Based on the observations of increased numbers of neutrophils in CF ELF, active NE in CF ELF was evaluated as a possible candidate for the signal that induced IL-8 gene expression in BET-1A cells.

First, NE inhibitors were evaluated for their ability to prevent CF ELF from inducing IL-8 gene expression in BET-1A cells (Fig. 3). Northern analyses demonstrated that resting cells had no IL-8 mRNA (lane 1) while CF ELF induced IL-8 mRNA transcripts (lane 2). Importantly, NE inhibitors such as SLPI (lane 3), α1AT (lane 4), PMSF (lane 5), or AAPV-CMK (lane 6) all blocked the induction of IL-8 gene expression. Further, an anti-TNF antibody did not suppress CF ELF induction of IL-8 gene expression (lane 7), although this same antibody was capable of inhibiting TNF-induced IL-8 gene expression in parallel cultures of BET-1A cells (lanes 8 and 9). In contrast to the IL-8 mRNA, β-actin gene expression did not change with any condition. Together, these observations strongly suggest that NE in CF ELF is responsible for the induction of IL-8 gene expression in the bronchial epithelial cells.

Neutrophil elastase induction of IL-8 gene expression in bronchial epithelial cells. Consistent with the hypothesis that the NE in CF ELF was the signal that upregulated IL-8 gene expression in BET-1A cells, Northern analyses demonstrated that purified NE increased IL-8 mRNA transcript levels in BET-1A cells in a similar fashion (Fig. 4, lane 1 and 2). Further,
the effect of NE could be blocked by the addition of NE inhibitors, including SLPI (lane 3), α1AT (lane 4), PMSF (lane 5), or AAPV-CMK (lane 6). Levels of control β-actin mRNA transcript were constant in all conditions. The upregulation of IL-8 mRNA transcripts by NE occurred in a dose- and time-dependent fashion (Fig. 5). IL-8 gene expression was observed at very low concentrations of NE (100 pM) and continued to increase up to 50 nM (A). Following a fixed dose (10 nM) of NE, IL-8 mRNA levels rapidly increased to its maximum at 3–6 h; it then decreased, but was still elevated at 24 h (B).

Figure 5. IL-8 mRNA levels in BET-1A human bronchial epithelial cells induced by NE. (A) Expression of IL-8 mRNA in response to increasing dose of NE in BET-1A cells. (B) Time course of IL-8 mRNA expression by BET-1A cells after exposure to NE (10 nM). Data shown in both panels are a representative of two individual experiments.
Figure 6. IL-8-related neutrophil chemotactic activity released by BET-1A human bronchial epithelial cells following stimulation with NE. Supernatants were collected from BET-1A cells incubated for 24 h, 37°C and evaluated for the presence of neutrophil chemotactic activity using a modified Boyden chamber. Shown are data for: FMLP (used as a positive control = 100% activity); IL-8; IL-8 incubated with anti-IL-8 antibody; resting BET-1A cells; BET-1A cells incubated with NE; anti-IL-8 antibody added to the supernatant of BET-1A cells incubated with NE; irrelevant IgG antibody added to the supernatant of BET-1A cells incubated with NE; and BET-1A cells incubated with NE + NE inhibitor AAPV-CMK. Data shown represent triplicate assay determinations of one example of three different experiments.

showed neutrophil chemotactic activity that was suppressed by anti-IL-8 antibody but not by preimmune rabbit IgG. Further, the addition of the NE-specific inhibitor AAPV-CMK in amounts sufficient to inhibit NE prevented NE from inducing BET-1A cells to release the neutrophil chemotactic activity. The results from the neutrophil chemotactic activity assay of CF ELF were uninterpretable because it was unclear how much of the total chemotactic activity in CF ELF was due to IL-8 as neutrophil migration was affected by the complex mixture of mediators, serum, bacterial, and intracellular components from damaged cells in the ELF of CF individuals.

Modulation of IL-8 gene expression in bronchial epithelial cells by neutrophil elastase. Isolated nuclei from resting BET-1A cells demonstrated a very low rate of IL-8 gene transcription (Fig. 7, lane 1). However, following stimulation with NE, the IL-8 gene transcription rate increased markedly over the resting level. Importantly, this upregulation of IL-8 gene transcription was blocked by α1AT (lane 3) and by SLPI (not shown). In contrast, the transcription rate of the c-myc gene or β-actin gene changed very little with NE stimulation (850% increase for IL-8 gene with NE compared with a 115% change for c-myc and a 160% change for β-actin).

The addition of NE to BET-1A cells did not change the stability of the IL-8 mRNA transcripts (Fig. 8). In this regard, following the inhibition of RNA synthesis with actinomycin D, IL-8 mRNA levels fell rapidly in resting BET-1A cells. The same pattern was observed in BET-1A cells exposed to NE. In contrast, in the presence of cycloheximide, the stability of IL-8 mRNA transcripts was markedly increased.

Discussion

Cystic fibrosis is characterized by chronic airway infection and inflammation invariably dominated by neutrophils. Although critical to host defense, neutrophils cause progressive damage to the airway epithelium by virtue of their potent mediators, most significantly NE, a destructive proteolytic enzyme (1, 10–19, 50, 51). Not only can NE damage epithelial cells by direct proteolytic effects, but also can hinder normal host defense by interfering with ciliary clearance, increasing mucus production, cleaving immunoglobulin and complement, and by impairing phagocytosis and killing of Pseudomonas aeruginosa by neutrophils (16, 17, 52–56). The present study demonstrates that the fluid lining the respiratory epithelium in CF contains large numbers of neutrophils and active NE, and that the NE in CF ELF is capable of inducing bronchial epithelial cells to express the gene for IL-8 and release neutrophil chemotactic activity as properties of IL-8.

BET-1A bronchial epithelial cells are transformed human bronchial epithelial cells. In the context that IL-8 is a potent neutrophil chemoattractant and activator (26–28), these obser-
vations, while made using a transformed bronchial cell line, likely represent the in vivo situation as evidenced by the absence of IL-8 from ELF of normal individuals and its presence in CF ELF at levels ranging from 8 to 108 nM, well above the usual IC_{50} for neutrophil responses to IL-8 (57). They suggest a scenario on the respiratory epithelium in CF, in which NE released by neutrophils induces bronchial epithelial cells to release IL-8, and the IL-8 recruits neutrophils that release NE, perpetuating the process.

While this succession of processes helps to explain the chronicity of neutrophil-dominated airway inflammation in CF in the absence of infection (and thus the chronic progressive airway damage), it begs the question as to what initiates the recruitment of the neutrophils. The answer to this is not known, but there are a number of possibilities, including normal host defense processes, such as those mediated by alveolar macrophages and/or complement (14, 20–24). Consistent with this concept, IL-8 mRNA transcripts have been observed in inflammatory cells recovered by lavage in CF, and IL-8 detected in CF ELF (58). Further, while the induction of IL-8 gene expression in bronchial epithelial cells by CF ELF is completely blocked by NE-inhibitors, it remains possible that other mediators may contribute to this process. In this regard, CF ELF contains a variety of other mediators, including TNF, interleukin-1, metalloprotease, and Pseudomonas elastase (15, 59–61). In addition, the presence of large numbers of neutrophils in CF ELF suggests that, in addition to NE, other neutrophil-processed mediators such as myeloperoxidase, collagenase, gelatinase, and proteinase 3 may also be present (13, 50). It is also possible that the bronchial epithelium may release chemotactants other than IL-8 (62–64). Thus, while NE appears to be a major signal for bronchial epithelial IL-8 gene expression in CF ELF, it is not necessarily the only signal and IL-8 expression is not necessarily the only response of the bronchial epithelium to the burden of inflammatory mediators it likely encounters.

NE induces an increase in the relative rate of transcription of the IL-8 gene in bronchial epithelial cells, but does not influence IL-8 mRNA transcript stability, suggesting the transcriptional process dominates in the response. However, the intracellular mechanisms of NE induction of IL-8 gene expression in bronchial epithelial cells are unknown. NE interacts with mononuclear phagocytes through a receptor on the surface of these cells (65), and can induce the release of glycoconjugates and sulfated macromolecules by bronchial epithelial cells (55, 66); this process might be linked to the same signal transduction pathway(s) to induce IL-8 gene expression.

Independent of the mechanisms involved, in the context that there are abundant neutrophils and NE in CF ELF, that NE induces IL-8 gene expression in human bronchial epithelial cells, that IL-8 is a potent chemotactrant and activator of neutrophils, and that inhibitors of NE suppress the ability of NE to induce IL-8 gene expression in bronchial epithelium, our observations suggest that local anti-NE therapy of CF may not only protect the epithelium from NE (12), but may also dampen the exaggerated recruitment of neutrophils to the lung in this disease. In this context, while caution must be used in not interfering with the necessity of neutrophils in the local host defense process, it is reasonable to suggest that anti-NE therapy, probably by direct aerosol administration, should be evaluated as a means of limiting the neutrophil-dominated airway inflammation in this disorder.

Acknowledgments

We thank Dr. L. Chang-Stroman, Pulmonary Branch, National Heart, Lung, and Blood Institute, for helping in this study, and T. Raymer for editorial assistance.

References


Neutrophil Elastase and Interleukin-8